Cayman Cpi-169; Purity- Greater Than Or Equal To 98%; Size- 5 Mg

Sparsentan is a dual antagonist of angiotensin II type 1 (AT₁) and endothelin receptor type A (ET_A; K_is = 0.8 and 9.3 nM, respectively, for the human receptors). It is selective for these receptors over AT₂ and ET_B receptors (K_is = >10 µM for both). Sparsentan inhibits angiotensin II-induced pressor responses in conscious normotensive rats (ED₅₀ = 3.6 µmol/kg, p.o). It reduces mean arterial pressure in spontaneously hypertensive rats when administered orally at doses of 10, 30, or 100 µmol/kg per day. Dietary administration of sparsentan (1,800 ppm) reduces albuminuria and inhibits development of glomerulosclerosis in the gddY mouse model of IgA nephropathy.

WARNING This product is not for human or veterinary use.